195 related articles for article (PubMed ID: 27862436)
1. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
[TBL] [Abstract][Full Text] [Related]
3. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
4. The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors.
Voruganti S; Lacroix JC; Rogers CN; Rogers J; Matts RL; Hartson SD
J Proteome Res; 2013 Aug; 12(8):3697-706. PubMed ID: 23763277
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein 90: inhibitors in clinical trials.
Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
[No Abstract] [Full Text] [Related]
6. Re-examining HSPC1 inhibitors.
Lee SL; Dempsey-Hibbert NC; Vimalachandran D; Wardle TD; Sutton PA; Williams JH
Cell Stress Chaperones; 2017 Mar; 22(2):293-306. PubMed ID: 28255900
[TBL] [Abstract][Full Text] [Related]
7. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.
Huyan T; Li Q; Dong DD; Yang H; Zhang J; Huang QS; Yin DC; Shang P
Immunopharmacol Immunotoxicol; 2016; 38(2):77-86. PubMed ID: 26642940
[TBL] [Abstract][Full Text] [Related]
9. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures.
Gulla A; Kazlauskas E; Liang H; Strupas K; Petrauskas V; Matulis D; Eshleman JR
Pancreas; 2021 Apr; 50(4):625-632. PubMed ID: 33939678
[TBL] [Abstract][Full Text] [Related]
10. How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?
Wang Y; Koay YC; McAlpine SR
ChemMedChem; 2017 Mar; 12(5):353-357. PubMed ID: 28139075
[TBL] [Abstract][Full Text] [Related]
11. Organelle-specific Hsp90 inhibitors.
Seo YH
Arch Pharm Res; 2015 Sep; 38(9):1582-90. PubMed ID: 26195286
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90 (HSP90) inhibitors activate the heat shock factor 1 (HSF1) stress response pathway and improve glucose regulation in diabetic mice.
Lee JH; Gao J; Kosinski PA; Elliman SJ; Hughes TE; Gromada J; Kemp DM
Biochem Biophys Res Commun; 2013 Jan; 430(3):1109-13. PubMed ID: 23261432
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition.
Kim HB; Lee SH; Um JH; Kim MJ; Hyun SK; Gong EJ; Oh WK; Kang CD; Kim SH
Int J Biol Sci; 2015; 11(8):923-34. PubMed ID: 26157347
[TBL] [Abstract][Full Text] [Related]
15. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
Beebe K; Mollapour M; Scroggins B; Prodromou C; Xu W; Tokita M; Taldone T; Pullen L; Zierer BK; Lee MJ; Trepel J; Buchner J; Bolon D; Chiosis G; Neckers L
Oncotarget; 2013 Jul; 4(7):1065-74. PubMed ID: 23867252
[TBL] [Abstract][Full Text] [Related]
16. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.
Wang Y; McAlpine SR
Chem Commun (Camb); 2015 Jan; 51(8):1410-3. PubMed ID: 25333923
[TBL] [Abstract][Full Text] [Related]
17. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
18. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Chen MH; Lin KJ; Yang WL; Kao YW; Chen TW; Chao SC; Chang PM; Liu CY; Tzeng CH; Chao Y; Chen MH; Yeh CN; Huang CY
Cancer; 2013 Jan; 119(2):293-303. PubMed ID: 22810956
[TBL] [Abstract][Full Text] [Related]
19. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.
Zhang MQ; Gaisser S; Nur-E-Alam M; Sheehan LS; Vousden WA; Gaitatzis N; Peck G; Coates NJ; Moss SJ; Radzom M; Foster TA; Sheridan RM; Gregory MA; Roe SM; Prodromou C; Pearl L; Boyd SM; Wilkinson B; Martin CJ
J Med Chem; 2008 Sep; 51(18):5494-7. PubMed ID: 18800759
[TBL] [Abstract][Full Text] [Related]
20. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.
Schaefer S; Svenstrup TH; Guerra B
PLoS One; 2017; 12(5):e0177706. PubMed ID: 28542269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
